论文部分内容阅读
血友病A是凝血因子Ⅷ缺乏引起的出血性疾病,凝血因子替代治疗是目前血友病A唯一有效的治疗措施.国内上市的替代治疗药物主要包括重组人凝血因子Ⅷ(重组FⅧ)和血源性人凝血因子Ⅷ(血源FⅧ).本文通过检索收集国内上市的7种FⅧ相关文献、药品说明书、诊疗指南、官方数据等,根据中国药品综合评价指南从药品基本信息、安全性、有效性、体内药学特性、药品质量、顺应性、经济性七方面对7种FⅧ制剂进行综合评价,以期为临床合理用药提供参考.“,”Hemophilia is an inherited hemorrhagic disease caused by the deficiency of the clotting factor Ⅷ, and the clotting factor Ⅷ replacement is the only effective treatment for patients with hemophilia A. Domestically listed drugs mainly include recombinant factor Ⅷ (rFⅧ) and plasma-derived factor Ⅷ (pdFⅧ). In this paper, domestic and foreign literatures, drug instructions, diagnosis and treatment guidelines and official data of domestically listed 7 kinds of FⅧ were collected. And a comprehensive review was made based on guideline of comprehensive evaluation for Drugs in China which included the following aspects: drug basic information, safety, efficiency, in vivo pharmaceutical characteristics, drug quality, compliance and pharmacoeconomics,in order to provide reference for rational drug use in clinical.